MoonLake Immunotherapeutics Reports 2025 Financials, Updates on SLK Clinical Pipeline, and Loan Facility Amendment

summarizeSummary

MoonLake Immunotherapeutics' annual report provides a comprehensive overview of its financial performance and clinical pipeline. The company reported a significant increase in net loss to $230.3 million in 2025, up from $121.2 million in 2024, reflecting increased R&D and G&A expenses as it advances its lead asset, SLK. Despite the widening loss, the company maintains a cash runway into the second half of 2027, supported by a $72.4 million public offering in November 2025. A notable financial event was the failure to meet Tranche 2 and 4 milestones for its Hercules Capital loan, which reduced committed funds by $175 million. However, a subsequent amendment to the loan agreement allowed for an additional $25 million draw, with $400 million remaining available. The filing also reiterates strong clinical progress for SLK across multiple indications, including positive Phase 3 data in HS, FDA Fast Track designation for PPP, and positive Phase 2 results in axSpA. An ongoing class action lawsuit and a new 10b5-1 trading plan by the CFO to sell a notable amount of shares are also disclosed.

check_boxKey Events

• Full Year 2025 Financial Results

  The company reported a net loss of $230.3 million for the year ended December 31, 2025, a significant increase from $121.2 million in 2024, driven by higher research and development and general and administrative expenses.

• Extended Cash Runway

  As of December 31, 2025, MoonLake had $394.0 million in cash, cash equivalents, and short-term marketable securities, projected to fund operations into the second half of 2027.

• Loan Facility Milestones Missed and Amended

  MoonLake failed to meet Tranche 2 and 4 milestones for its $500 million Hercules Capital loan facility due to a higher-than-expected placebo response in the VELA-2 trial, reducing committed funds by $175 million. A subsequent amendment on February 20, 2026, allowed for a $25 million draw from the second tranche, with up to $400 million remaining available.

• 2025 Public Offering Completed

  In November 2025, the company completed a public offering of 7,142,857 Class A Ordinary Shares at $10.50 per share, generating net proceeds of $72.4 million.

auto_awesomeAnalysis

MoonLake Immunotherapeutics' annual report provides a comprehensive overview of its financial performance and clinical pipeline. The company reported a significant increase in net loss to $230.3 million in 2025, up from $121.2 million in 2024, reflecting increased R&D and G&A expenses as it advances its lead asset, SLK. Despite the widening loss, the company maintains a cash runway into the second half of 2027, supported by a $72.4 million public offering in November 2025. A notable financial event was the failure to meet Tranche 2 and 4 milestones for its Hercules Capital loan, which reduced committed funds by $175 million. However, a subsequent amendment to the loan agreement allowed for an additional $25 million draw, with $400 million remaining available. The filing also reiterates strong clinical progress for SLK across multiple indications, including positive Phase 3 data in HS, FDA Fast Track designation for PPP, and positive Phase 2 results in axSpA. An ongoing class action lawsuit and a new 10b5-1 trading plan by the CFO to sell a notable amount of shares are also disclosed.